baber/WOPTO huggingface dataset:
Patent NZ-282893-A (NZ)
Title: Pyridine derivatives substituted with thiazolidine or oxazolidine rings and medicaments thereof
Inventor: OHARA YOSHIO
IPC: A61P3/10
Filed: 1995-03-27
Abstract: The present invention provides novel pyridine type thiazolidines and their salts, expressed by formula (I) (wherein X<1> is S or O; X<2> is S, O or NH; Y is CR<6>R<7>, R<6> is a hydrogen atom, a C1-C7 alkyl group or a C3-C7 cycloalkyl group, and R<7> is a hydrogen atom, a C1-C7 alkyl group or a C3-C7 cycloalkyl group or forms a bond together with R<4>), or SO2; Z is a C1-C10 alkyl group, a C2-C10 alkenyl group, a C2-C10 alkynyl group, a C3-C7 cycloalkyl group, a C3-C7 cycloalkenyl group (each of said alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl groups may be substituted with at most 3 of hydroxyl, oxo, C1-C7 alkyl and C1-C7 alkoxy groups), a phenyl group, a biphenyl group, an  alpha -naphthyl group, a  beta -napthyl group, a benzyl group or a heterocyclic group. The compounds have a hypoglycemic effect.
Patent NZ-314036-A (NZ)
Title: Rj spring block molded into gel and inserted into rj socket
Inventor: SHIMIRAK GERALD L
IPC: H04Q1/02
Filed: 1994-01-12
Abstract: An RJ type telephone connector spring block for forming an environmentally sealed RJ type telephone socket, said spring block comprising:     a spring block body; a plurality of RJ type telephone socket contacts mounted to said spring block body; a plurality of wires electrically coupled to said RJ type telephone socket contacts; and a quantity of gel encapsulating said spring block body and at least a major portion of said RJ type telephone contacts adjacent said spring block body, wherein said encapsulated spring block is operably insertable into an RJ type telephone socket housing so as to form an environmentally sealed RJ type telephone socket.   <IMAGE>
Patent NZ-331091-A (NZ)
Title: Building wall for resisting lateral forces comprises frame with planar sheet affixed thereto
Inventor: COLONIAS KAREN W
IPC: E04B1/26
Filed: 1998-07-27
Abstract: A wall designed to resist lateral forces imposed on a building incorporating the wall comprises a bottom plate 3 with means for connecting plate 3 to an underlying structural component 2 and a top plate 7 resting on studs 5 with means for connecting top plate 7 to studs 5.  A shear resisting assembly 9 is connected to top plate 7 and also to underlying structural component 2 and is disposed between top plate 7 and underlying structural component 2.  Shear resisting assembly 9 comprises planar shear resisting element 10 (not shown), a top strut 17, bottom strut 18, a first chord 19, second chord 20 and means for connecting these components together.
Patent NZ-331373-A (NZ)
Title: Use of hydrolysed polymers of n-vinyl carboxylic acid amides as agents for increasing the dry strength of paper, card and cardboard
Inventor: NIESSNER MANFRED
IPC: D21H17/45
Filed: 1997-02-20
Abstract: PCT No. PCT/EP97/00801 Sec. 371 Date Aug. 31, 1998 Sec. 102(e) Date Aug. 31, 1998 PCT Filed Feb. 20, 1997 PCT Pub. No. WO97/31518 PCT Pub. Date Sep. 4, 1997Partially hydrolyzed polymers of N-vinylcarboxamides obtainable by sole polymerization of N-vinylcarboxamides of the formula where R1 and R2 are each hydrogen or C1- to C6-alkyl, and elimination from the polymers of from 0.5 to 95 mol % of the groups of the formula where R1 is hydrogen or C1- to C6-alkyl, can be used as paper, paperboard and cardboard dry strength enhancers.
Patent NZ-332372-A (NZ)
Title: Prepayment for wireless telephone services by means of smart cards
Inventor: MARTINEAU PHILIPPE
IPC: G07F7/10
Filed: 1997-04-11
Abstract: Disclosed is a prepaid smart card to be used in a wireless telephone network and method for prepaying for wireless telephone services, and a system for operating a wireless telephone network with prepaid smart cards. The cards, method and system permit the use of wireless telephones anonymously, and/or the payment by a user without having a subscription. It is stated that  minimal changes are required to the existing wireless telephone and wireless telephone network, yet security against abuse or fraudulent use of the system is provided. Additionally, promotional material may be provided with the prepayment or persons may prepay into a subscriber's telephone.
Patent NZ-336544-A (NZ)
Title: Method for synthesis of rhizoferrin being useful as heavy metal chelators, specifically iron overload diseases such as thalassemia
Inventor: BERGERON RAYMOND J
IPC: C07C235/10
Filed: 1998-01-08
Abstract: A method for synthesizing a compound of the Formula (I), applicable to the preparation of compounds embodying a citric acid moiety of particular enantiometric configuration coupled via an amide linkage to an amine. The preferred embodiment describes the synthesis of rhizoferrin. Wherein: C* is a chiral carbon atom; a and b may be the same or different and are integers from 0 to 10, inclusive; and R is H, alkyl, arylalkyl, carboxyl or Formula (Ia) wherein C* and b have the meanings ascribed above, comprising: (1) Acylating a polyamine of the Formula (II): wherein: a, b and R have the meanings ascribed above, and Q is an amine protective group, with a diester of citric acid having the Formula (III): wherein: R' is alkyl, aryl, aralkyl or cycloalkyl having up to 10 carbon atoms, to produce an amide having the Formula (IV) (2) Hydrolyzing amide (IV) to produce an acid having the formula (V) (3) Deprotecting acid (V) to remove the Q groups, thereby producing an acid of formula (I).
Patent NZ-502296-A (NZ)
Title: Dolastatin 15 derivatives
Inventor: JANSSEN BERND
IPC: C12P19/34
Filed: 1998-07-07
Abstract: Compound of formula: A-B-D-E-F-(G)r-(K)s-L wherein: A is a proline derivative of formula IIa, wherein na is O to 3; Ra I hydrogen, or unsubstituted or fluorine-substituted normal, branched or cyclic C1-3-alkyl; R1a is hydrogen, C1-3 -alkyl, phenyl, or substituted phenyl; or Ra and R1a together form a propylene bridge; and R2a, R3a, R4a and R5a are each, independently, hydrogen or alkyl; or an alpha-amino acid derivative of Formula IIIa, Formula IVa, Formula Va, Formula VIa, Formula VIIa, Formula VIIIa, a 2-azabicyclo heptane-3-carboxylic acid derivative of Formula IXa, an amino acid derivative of Formula Xa; B is a valyl, isoleucyl, allo-isoleucyl, norvalyl, 2-tert-butylglycyl or 2-ethylglycyl residue; or an alpha-amino acid residue of Formula IIb;  D is an N-alkylvalyl, N-alkyl-2-ethylglycyl, N-alkyl-2-tert-butylglycyl, N-alkylnorleucyl, N-alkylisoleucyl, N-alkyl-allo-isoleucyl or N-alkylnorvalyl residue; or an alpha-amino acid residue of Formula IId, Formula IIId; E is a prolyl, thiazolidinyl-4-carbonyl, homoprolyl, or hydroxyprolyl residue; or an alpha-amino acid residue of Formula IIe; or an aminocyclopentanecarboxylic acid residue of Formula IIIe, wherein Re is alkyl and R1e is hydrogen, or unsubstituted or fluorine-substituted alkyl;  F is a prolyl, thiazolidinyl-4-carbonyl, homoprolyl or hydroxyprolyl residue; or an alpha-amino acid residue of Formula IIf; or  a 2- or 3-aminocyclopentanecarboxylic acid residue of Formula IIIf; G is an alpha-amino acid residue of Formula IIg; K is an alpha-amino acid of Formula IIk; and  L is a substituted or unsubstituted amino, hydrazido, aminoxy or oximato group; and r and s are independently, 0 or 1; provided that when s and r are 0 and A is of formula IIa where na is 0 or 1 and R1a, R2a, R3a, R4a and R5a are each hydrogen, L is a substituted or unsubstituted amino or hydrazido group .
Patent NZ-506429-A (NZ)
Title: Erythropoietin liposomal dispersion
Inventor: DELMENICO SANDRO
IPC: A61K47/16
Filed: 1999-02-12
Abstract: The  present  invention relates to  a  liposome  based formulation  of erythropoietin comprising: (a) an  effective amount   of   an   erythropoietin;  (b)  a   lipidic   phase comprising:  (i)  lecithin  or hydrogenated  lecithin;  (ii) optionally,  a  charged electropositive  or  electronegative lipid  compound;  and  (iii)  cholesterol  or  a  derivative thereof   selected  from  cholesterol  esters,  polyethylene glycol  derivatives  of cholesterol (PEG-cholesterols),  and organic  acid  derivatives  of  cholesterols;  and   (c)   a phosphate buffer. The liposome based parenteral dosage  form of  the  invention  is  prepared  by  means  of  an  ethanol injection  technique. The composition avoids  the  need  for use of human serum albumin and exhibits superior stability.
Patent NZ-508147-A (NZ)
Title: Knee brace bracket for tilt-up construction
Inventor: TRUITT ROBERT E
IPC: E04G21/26
Filed: 2000-03-20
Abstract: A knee brace bracket 10Æ for a knee bracing structure 11Æ connecting a main brace 14 which extends between a panel 12 and a floor slab 20 to first and second knee braces 16a, 16b. The knee brace bracket 10Æ has a frame including a passage defining a longitudinal axis for rotatably receiving a main brace, and is pivotally connected to each of the side braces 16a, 16b to permit a screw adjustment for the length of the main pipe for in situ adjustment of the knee bracing structure.
Patent NZ-514014-A (NZ)
Title: Method of treating sleep apnoea
Inventor: CHEETHAM SHARON CRAWFORD
IPC: A61P25/20
Filed: 2000-03-17
Abstract: The use of a compound of formula I including enantiomers and pharmaceutically acceptable salts thereof in which R1 and R2 are independently H or methyl, in the manufacture of a medicament for treating sleeping disorder including sleep apnoea and snoring.
Patent NZ-521282-A (NZ)
Title: Heat exchanger with two-stage heat transfer
Inventor: TAWNEY JEFFERY
IPC: F28D7/02
Filed: 2002-09-10
Abstract: A tube and shell heat exchanger is formed by a shell enclosing an internal sidewall which in turn receives an internally located flow controller outer and inner heat exchange cavities are formed between the outer shell and the internal shell and the internal shell and the flow controller, respectively. Helical convolutions of the conduit are provided in each of the heat exchange cavities for counter concurrent flow of fluid medium from one cavity to another. A bottom wall closes off the outer shell.
Patent NZ-521459-A (NZ)
Title: Methods of producing a terminally sterilized topical patch preparation
Inventor: SHUDO JUTARO
IPC: B65B55/08
Filed: 2001-03-22
Abstract: A method of producing a terminally sterilized topical patch preparation comprising: - exposing a topical patch preparation to electron beam radiation for a period of time sufficient to terminally sterilize said topical patch preparation, - producing a terminally sterilized topical patch preparation. The topical patch may be packaged and sealed in an aluminum layer. The topical patch may be an adhesive gel composition comprising: - an active ingredient, such as a local anesthetic. - a water soluble polymer gel, - water, and - a water holding agent. Also a kit for a transdermal patch as described above which includes instructions for use is disclosed.
Patent NZ-523449-A (NZ)
Title: Pyrroloquinolones as antiviral agents
Inventor: VAILLANCOURT VALERIE A
IPC: A61K31/5377
Filed: 2001-06-25
Abstract: Pyrroloquinolone compounds of formula (I) that are useful as antiviral agents, in particular, as agents against viruses of the herpes family are disclosed, wherein the substituents R1 to R6 are as defined in the specification.
Patent NZ-524338-A (NZ)
Title: Seat for a reclining office chair with depth adjustment and transverse folding
Inventor: PRINCE JONATHAN WILLIAM
IPC: A47C1/03
Filed: 2001-09-03
Abstract: Disclosed is a seat portion 14 for a seat wherein the seat portion 14 has a panel with a rear portion to support the occupant. The rear portion has a longitudinal centerline and has two zones 162 either side of the centerline. Each zone has a first pattern of weakeners arranged in a series of spaced sinuous lines. A substantial portion of the panel, apart from the zones 162 may also be provided with a pattern of weakeners arranged in a series of spaced sinuous lines 163 interrupted by the zones 162. (62) Divided out of 513928
Patent NZ-529448-A (NZ)
Title: Castanospermine esters for treating flavivirus infections
Inventor: TYMS ALBERT STANLEY
IPC: C07D471/04
Filed: 2002-05-02
Abstract: A castanospermine ester is described to be used in the manufacture of a medicament for the therapy or prophylaxis of a Flavivirdae infection. The medicament is disclosed to comprise a castanospermine ester of formula (I), wherein R, R1 and R2 are independently selected from the following substitutents: hydrogen; C1-14 alkanoyl; C2-14 alkenoyl; cyclohexanecarbonyl; C1-8 alkoxyacetyl; naphtha-lenecarbonyl optionally substituted by methyl or halogen; phenyl(C2-6 alkanoyl) wherein the phenyl is optionally substituted by methyl or halogen; cinnamoyl; pyridinecarbonyl optionally substituted by methyl or halogen; dihydropyridine carbonyl optionally substituted by methyl or halogen; dihydropyridine carbonyl optionally substituted by C1-10 alkyl; thiophenecarbonyl optionally substituted by methyl or halogen; furancarbonyl optionally substituted by methyl or halogen; or a compound of the formula (II) wherein Y is hydrogen, C1-4 alkyl, C1-4 alkoxy, halogen, trifluoromethyl, C1-4 alkyl, C1-4 alkylsulphonyl, C1-4 alkylmercapto, cyano or dimethylamino; Y' is hydrogen, C1-4 alkyl, C1-4 alkoxy or halogen; wherein at least one, but not more that two, of R, R1 and R2 is hydrogen; or a pharmaceutically acceptable salt or derivative thereof.
Patent NZ-532367-A (NZ)
Title: HEPTA-, OCTA- and nonapeptides having antiangiogenic activity
Inventor: HAVIV FORTUNA
IPC: A61K38/08
Filed: 2002-10-30
Abstract: Hepta-, octa- and nanopeptides are described. The peptides are useful in pharmaceuticals for inhibiting angiogenesis and treating cancer.
Patent NZ-534876-A (NZ)
Title: Human beta-secretase enzyme, inhibitors and their compositions and uses
Inventor: ANDERSON JOHN P
IPC: A01K67/027
Filed: 2000-02-10
Abstract: Described are isolated fragments and purified forms of a beta-secretase enzyme protein in which the isolated fragments lack a transmembrane region and exhibits beta-secretase activity. The beta-secretase enzyme protein is implicated in the production of amyloid plaque components which accumulate in the brains of individuals afflicted with Alzheimer's disease. Recombinant cells that produce this enzyme, methods and kits for screening compounds that inhibit beta-amyloid production are also described. These compositions are useful for use in methods of selecting compounds that modulate beta -secretase. Inhibitors of beta -secretase are implicated as therapeutics in the treatment of neurodegenerative diseases, such as Alzheimer's disease.
Patent NZ-535143-A (NZ)
Title: Benzamide derivatives useful as histone deacetylase inhibitors for the treatment of cancer
Inventor: ROBERTS CRAIG ANTHONY
IPC: C07D413/04
Filed: 2003-04-02
Abstract: Benzamide derivative compounds of the formula (I), their pharmaceutically-acceptable salts and in-vivo-hydrolysable ester and amide are disclosed, wherein Ring A is a pyridyl, quinolyl, indolyl, pyrimidinyl, morpho1iny piperazinyl, pyradazinyl, pyrazinyl, thiazolyl, thienyl, thienopyriniidinyl, thienopyridinyl, purinyl, triazinyl, oxazolyl, pyrazolyl, or furanyl; wherein if Ring A contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from K; m is 0-4 and each R1 is a group such as hydroxy, halo, trifluoromethyl and cyano; R2 is halo and n is 0-2; and each R4 is a group such as hydroxy, halo, trifluoromethyl and cyano; p is 0-4; and R3 is amino or hydroxy (these variables are further defined in the specification). Also disclosed are processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by histone deacetylase. These compounds are suitable for treating cancer.
Patent NZ-537989-A (NZ)
Title: Devices and methods for producing a product from frozen material
Inventor: ROBINSON LANCE WILLIAM
Filed: 2005-07-14
Abstract: Devices for processing frozen blocks of material, such as a fruit mixture, fruit and cream mixture, or fruit and yoghurt mixture, and methods for their use are disclosed. The devices have an auger within a mixing tube (5, 6) and the frozen material enters the tube at a right angle to the axis of the auger and tube. The auger may have at least one threaded section that cuts and shears the frozen material to force the resulting product out an orifice. In an alternative embodiment the auger and missing tube includes a cylindrical section and a conical section, both sections acting to cut and shear the frozen material while moving the resulting product out an orifice.
Patent NZ-541168-A (NZ)
Title: Levalbuterol salt
Inventor: MCGLYNN PAUL
IPC: A61K9/14
Filed: 2003-12-08
Abstract: Disclosed is the use of levalbuterol L-tartrate in the manufacture of a metered dose inhaler for the treatment of bronchospasm in a patient. Also disclosed are metered dose inhalers comprising levalbuterol L-tartrate in crystalline form and processes for the preparation of levalbuterol L-tartrate.
Patent NZ-542129-A (NZ)
Title: Method for deactivating and reactivating security modules
Inventor: KUDELSKI HENRI
IPC: G06F21/62
Filed: 2004-03-02
Abstract: Method for deactivating and reactivating security modules, particularly for controlling access to conditional-access data is disclosed. Such security modules comprise a plurality of registers (R1, R2, R3, Rn) containing values. The method comprises a step of sending by an operator at least one management message (RUN-EMM) containing an executable code which is loaded into a security module memory then executed. The execution of the executable code modifies in a reversible way the values contained in the registers. The content of the registers after modification render the module unusable and the values of the register after modification directly depend on the content of these registers before modification. The method also enables previously deactivated security modules to be reactivated by means of a step of transmitting a further message containing an executable code (RUN-EMM-1) for reactivating the modules, which executable code has an opposite function to that of the executable code used to deactivate the security modules.
Patent NZ-542427-A (NZ)
Title: Therapeutic, prophylactic and diagnostic agents relating to TLR-2 and TLR-4
Inventor: VISVANATHAN KUMAR
IPC: C12Q1/68
Filed: 2004-03-19
Abstract: Provided is an in vitro antibody-based diagnostic assay to detect infection of a subject by a Hepatitis virus, said assay comprising determining the level of TLR-2 and TLR-4 using antibodies specific to TLR-2 or TLR-4 wherein an elevated level of TLR-2 is indicative of infection by Hepatitis C virus (HCV) infection and a reduced level of TLR-2 and TLR-4 is indicative of Hepatitis B virus (HBV) infection, said levels compared to an subject infected with neither HCV nor HBV. Further provided are similar methods for determining if a patient will respond to treatment or for monitoring a response to treatment. Also provided is the use of TLR-2 or TLR-4 antibody in the manufacture of a medicament for treating a subject infected with HCV or HBV.
Patent NZ-545695-A (NZ)
Title: Method of combining welding and adhesive bonding for joining metal components
Inventor: STOL ISRAEL
IPC: B23K11/34
Filed: 2004-08-30
Abstract: An assembly of joined metal components is disclosed. The assembly of joined metal components comprises a first component having an exposed surface and a first joint surface; a second component having a second joint surface abutting the first joint surface, and having at least one recess forming a space between the first joint surface and the second component. Adhesive material completely fills the space formed by the recess in the second component and the first joint surface of the first component. The adhesive material is substantially enclosed within the recess. A fusion or solid-state weld extends from the exposed surface into the second component.
Patent NZ-545889-A (NZ)
Title: Ocular diagnosis of Alzheimer's disease
Inventor: GOLDSTEIN LEE E
IPC: G01N33/566
Filed: 2002-04-25
Abstract: A method of diagnosing Alzheimer' s disease in a mammal is described. It comprises contacting an ocular tissue with a detectably-labelled compound which binds to an amyloid protein. An increase in binding of the compound to the ocular tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's disease.
Patent NZ-552803-A (NZ)
Title: (1S,5S)-3-(5,6-dichloropyridin-3-YL)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
Inventor: WAYNE GREG S
IPC: C07D487/04
Filed: 2005-07-08
Abstract: Disclosed is a crystalline (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate demonstrating at least one characteristic peak in the powder X-ray diffraction pattern at values of two theta of 8.8 +/- 0.2, 11.8, 13.7, 15.1, 17.2, 18.5, 18.9, 20.6, 24.4, 24.7, and 27.4 +/-0.2, Also disclosed is amorphous (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6 diazabicyclo [3.2.0]heptane benzenesulfonate.
Patent NZ-554389-A (NZ)
Title: Incrementing a value which increases a chance of triggering a game
Inventor: WRIGHT DEAN
IPC: G07F17/34
Filed: 2005-11-08
Abstract: Disclosed is a method for providing a game in a gaming machine in a gaming establishment based on an increasing chance. The method includes: storing a game credit value; receiving an input message from one of multiple input terminals and providing a value adjustment message in response; incrementing the value in response to the adjustment message; generating a game trigger message causing a game terminal to execute the game with at least a portion of the credit value as stake value; storing a predetermined game trigger value; and comparing the game credit value to the game trigger value. The game trigger message is generated in response to the comparison when predetermined criteria are met, such that incrementing the credit value increases the chance of causing the game to be executed.
Patent NZ-555916-A (NZ)
Title: Method and apparatus for collecting a blood component and performing a photopheresis treatment
Inventor: GARA STEPHEN
Filed: 2005-12-19
Abstract: A method of collecting a desired lower density component of buffy coat or a higher density component of buffy coat comprising: providing a separator having an inlet, a first outlet, and a second outlet; adding an anticoagulant fluid to whole blood obtained from a patient or a blood donor in a predetermined ratio to form a mixture of whole blood and anticoagulant fluid; pumping the mixture of whole blood and anticoagulant fluid into the separator via the inlet at a selected inlet rate; separating the mixture into blood components of different densities; withdrawing plasma and red blood cells from the separator while continuing to pump the mixture of whole blood and anticoagulant fluid into the separator, the plasma and red blood cells being withdrawn at rates so as to build up buffy coat in the separator, the plasma being withdrawn via the first outlet and the red blood cells being withdrawn via the second outlet; and upon a predetermined amount of buffy coat building up in the separator, collecting the buffy coat from the separator by discontinuing the withdrawal of red blood cells from the second outlet, thereby causing the red blood cells to push the buffy coat out of the separator via the first outlet; rinsing the separator with a saline solution; pumping the collected buffy coat back to the separator via the inlet; and separating the collected buffy coat into a higher density buffy coat layer and a lower density buffy coat layer.